Hostname: page-component-84b7d79bbc-g78kv Total loading time: 0 Render date: 2024-08-01T19:46:11.421Z Has data issue: false hasContentIssue false
  • English
  • Français

University Contributions to the HPV Vaccine and Implications for Access to Vaccines in Developing Countries: Addressing Materials and Know-How in University Technology Transfer Policy

Published online by Cambridge University Press:  06 January 2021

Sara E. Crager ,
Ethan Guillen  and
Matt Price
Sara E. Crager
Affiliation:
Yale University; McGill University
Ethan Guillen
Affiliation:
Yale University
Matt Price
Affiliation:
The College of William and Mary
Get access Rights & Permissions [Opens in a new window]

Abstract

Human Papillomavirus (HPV) is a major cause of morbidity and mortality worldwide, with most of the disease burden concentrated in developing countries. Over 90 percent of cervical cancer deaths, almost all of which are caused by HPV, occur in low- and middle-income countries where access to goods and services for prevention and treatment pose major barriers to intervention. In resource-poor settings lacking the capacity for routine screening for cervical cancer, the HPV vaccines developed by Merck and GlaxoSmithKline are desperately needed to help prevent these unnecessary deaths. The initial development of currently available HPV vaccines took place at a number of universities and other publicly funded institutions, yet there is little low-cost access to the vaccine in developing countries where access would be most critical. This is the rule rather than the exception with most university-discovered medicines. Universities and other publicly-funded institutions can adopt a number of licensing methods to ensure that vaccines discovered on their campuses are available at low-cost in developing countries. Universities Allied for Essential Medicines has proposed that universities adopt Global Access Licensing policies to implement these changes by enabling generic or low-cost production of the end product in developing countries. Generic competition is a critical market force that has, for instance, driven down the price of HIV/AIDS treatments from more than $10,000 to less than $99 per patient per year today. While the central barrier to creation of small molecule generics is patent-protection, there are multiple additional barriers that need to be addressed in order to ensure the efficient production of cost-effective generic vaccines and other biologics. While certain biologics may require generic producers to perform additional clinical trials, vaccines are in a somewhat unique situation with respect to both safety and efficacy. With access to appropriate patents, materials and knowledge, vaccines have the potential to be evaluated efficiently and cost-effectively via a pathway parallel to establishing bioequivalence for generic small molecule drugs. A new paradigm is needed that addresses the additional barriers that exist, outside of simply patent protection, to the generic production of vaccines and other biologics. One possible framework, which builds upon previous work on prize funds and patent pools, is discussed here: a Patents, Materials, and Know-how Pool (PMK Pool), based on the patent pool model such as those outlined in the Essential Medical Inventions Licensing Agency and proposals recently put forth by the governments of Barbados and Bolivia. University approaches to licensing vaccines and other biologics need to ensure access not only to patents, knowledge, and materials covered by intellectual property, but must also address the problem of access to materials and know-how that are often proprietary trade secrets. Universities should actively participate in the creation of this and other novel mechanisms, and in the meantime use currently available technology transfer mechanisms to ensure low-cost access to medicines in developing countries.

Type
Article
Information
American Journal of Law & Medicine , Volume 35 , Issue 2-3 , June 2009 , pp. 253 - 279
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

†††

Serves on Board of Directors of UAEM. The views expressed in this paper do not necessarily represent those of his employer.

References

1 Executive Board, World Health Organization, Implementation of Resolutions: Progress Reports, 4 (Jan. 2, 2007) available at http://www.who.int/phi/B120_35_Add1-en.pdf.

2 Id. at 4.

3 Id.

4 Id.

5 Fields Virology 59 (David M. Knipe et al. eds., 5th ed. 2007).

6 Id. at 513.

7 Id. at 2302.

8 Id.

9 Id. at 513.

10 Id. at 2339.

11 Id.

12 Id.

13 Zhou, Jian et al., Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-like Particles, 185 Virology 251, 251 (1991).CrossRefGoogle ScholarPubMed

14 Ghim, Shin-Je et al., HPV-1 L1 Protein Expressed in cos Cells Displays Conformational Epitopes Found on Intact Virions, 190 Virology 548, 548 (1992).CrossRefGoogle ScholarPubMed

15 Kirnbauer, R. et al., Papillomavirus L1 Major Capsid Protein Self-Assembles into Virus-Like Particles that are Highly Immunogenic, 89 Proc. Nat’l Acad. Sci. USA 12180, 12180-4 (1992).CrossRefGoogle ScholarPubMed

16 Kirnbauer, R. et al., Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles, 67 J. Virol. 6929-36 (1993).CrossRefGoogle ScholarPubMed

17 Id.

18 Id.

19 McNeil, Caroline, News, Who Invented the VLP Cervical Cancer Vaccines?, 98 J. Nat’l Cancer Inst. 433, 433 (2006).CrossRefGoogle Scholar

20 Id.

21 Press Release, Merck, FDA Approves Merck's GARDASIL® to Protect Against Two Additional Cancers (Sept. 12, 2008) available at http://www.merck.com/newsroom/press_releases/product/2008_0925.html.

22 Grimes, Janelle L., HPV Vaccine Development: A Case Study of Prevention and Politics, 34 Biochemistry & Molecular Biology Ed. 148, 151 (2006).CrossRefGoogle ScholarPubMed

23 Event Brief, Merck, 4Q 2007 Merck & Co., Inc. Earnings Conference Call – Final (2007), available at http://insurancenewsnet.com/article.asp?n=1&neID=20080130560.2_16e40cd824e653c3.

24 Transcript, Merck & Co. Inc. Q3 2008 Earnings Conference Call (Oct. 22, 2008) available at http://seekingalpha.com/article/101228-merck-co-inc-q3-2008-earningsconference-call-transcript?page=1.

25 Press Release, Merck, supra note 21.

26 Centers for Disease Control and Prevention, HPV Vaccine Information for Young Women, http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine-young-women.htm (last visited April 2, 2009).

27 Centers for Disease Control and Prevention, CDC Vaccine Price List, http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm#pediatric (last visited Nov. 2008).

28 Agosti, Jan M. & Goldie, Sue J., Introducing HPV Vaccine in Developing Countries – Key Challenges and Issues, 356 New Eng. J. Med. 1908, 1909 (2007).CrossRefGoogle ScholarPubMed

29 Effort, April E. & Stevens, Ashley J., Using Academic License Agreements to Promote Global Social Responsibility, 43 Les Nouvelles: J. Licensing Executives Soc’y 85, 87 (2008).Google Scholar

30 Jonathan J. Jensen et al., The Role of Public Sector Research in the Discovery of New Drugs, Poster at Annual Meeting, Association of University Technology Managers, San Francisco, CA, March 2007.

31 Id.

32 Ass’n Univ. Tech. Managers, Licensing Survey FY2006 4 (2006).

33 Gareth Williams, James Robertson, & Mike Gilbert, Marks & Clerk Biotechnology Report 2007 (2007).

34 World Health Org., Equitable Access to Essential Medicines: A Framework for Collective Action, in Policy Perspectives on Medicine 1 (2004).

35 White Paper, Cal. Inst. Tech.et al., In the Public Interest: Nine Points to Consider in Licensing University Technology, 1 (2007), available at http://otl.stanford.edu/industry/resources/whitepaper-10.pdf.

36 Id. at 8.

37 Ass’n Univ. Tech. Managers, Endorse the Nine Points to Consider, http://www.autm.net/source/NinePoints/ninepoints_endorsement.cfm (Apr. 3, 2008).

38 Andreas Billich, HPV vaccine MedImmune/GlaxoSmithKline, 4 Current Opinion in Investigational Drugs 210-13 (2003); Grimes, supra note 22, at 2 (noting that Commonwealth Serum Laboratories, a commercial partner of the University of Queensland, retained the rights in Australia and New Zealand).

39 Amy Gardner, Drugmaker Assists in Pushing for Mandate for HPV Vaccination, Wash. Post, Feb. 11, 2007, at C05.

40 Agosti & Goldie, supra note 28, at 1909.

41 Bloom, Stacie, News, Q & A with the man who can stop cervical cancer in its tracks, 115 J. Clinical Investigation 2587, 2587 (2005).CrossRefGoogle ScholarPubMed

42 Id.

43 Letter from Robert Berdahl, President, American Association of Universities, to US Representatives Anna Eshoo and Joe Barton (June 10, 2008), http://www.aau.edu/WorkArea/showcontent.aspx?id=6130.

44 Grabowski, Henry, Outlook: Follow-on biologics: data exclusivity and the balance between innovation and competition, 7 Nature Reviews Drug Discovery 479, 479-88 (2008).CrossRefGoogle Scholar

45 Outterson, Kevin & Kesselheim, Aaron S., Market-Based Licensing for HPV Vaccines in Developing Countries, 27 Health Affairs 130, 130-39 (2008).CrossRefGoogle ScholarPubMed

46 U.S. Food and Drug Administration, Generic Competition and Drug Prices, (2006), available at http://www.fda.gov/cder/ogd/generic_competition.htm, (last visited Nov. 18, 2008).

47 Medecins Sans Frontieres, Untangling the Web of Price Reductions: A Pricing Guide for Developing Countries, available at http://doctorswithoutborders.org/publications/reports/2005/untanglingthewebv8.pdf.

48 See, for example, Effort and Stevens for a discussion of licensing mechanisms that can achieve this end. One example provided by Effort and Stevens achieves this by altering the standard definition of “patent rights” in the licensing terms to include follow-on patents for the purposes of executing the universities access policy. Effort & Stevens, supra note 29, at 85- 101. For a discussion of capturing future improvements through a grant-back mechanism see, Amy Kapczynski et al, Addressing Global Health Inequities: An Open-Licensing Approach for University Innovations, 20 Berkeley Tech. L.J. 1031 (2005).

49 World Health Organization, World Health Statistics 2008, available at http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf.

50 Tarzian Sorensen, Jill Ann & Chambers, Donald A., Evaluating Academic Technology Transfer Performance by How Well Access to Knowledge if Facilitated-Defining an Access Metric, 33 J. Tech. Transfer 534, 541-43 (2007).CrossRefGoogle Scholar

51 The annual survey by the Association of University Technology Managers (AUTM) (one of the largest systematic surveys of university technology transfer activity), for instance, only measures metrics such as the number of patents, licenses executed and revenues received from licensing activity. The Association of University Technology Managers, http://www.autm.net/surveys/ (last visited Mar. 30, 2009). The Better World Project, also led by AUTM, offers vignettes on university technology transfer activities that have helped society but there is no related, systematically collected data. The Better World Project, http://www.betterworldproject.net/reports.cfm (last visited Mar. 30, 2009).

52 Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No.98-417, 98 Stat. 1585 (1984).

53 Roger, S. D. & Goldsmith, D., Biosimilars: it's not as simple as cost alone, 33 J. Clinical Pharmacy & Therapeutics 459, 461 (2008).CrossRefGoogle Scholar

54 Karpusas, M., Whitty, A., Runkel, L., & Hochman, P., The structure of human interferon-beta: implications for activity, 54 Cell and Molecular Life Sci. 1203, 1203–16 (1998).CrossRefGoogle ScholarPubMed

55 JoAnn A. Suzich et al., SystemicImmunization with Papillomavirus L1 Protein Completely Prevents the Development of Viral Mucosal Papillomas, 92 Proc. Nat’l Acad. Sci. USA 11553, 11553-57 (1995).

56 Hofmann, Kathryn J. et al., Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-like Particles in Saccharomyces Cerevisiae, 209 Virology 506, 506-18 (1995).CrossRefGoogle ScholarPubMed

57 Giezen, Thijs J. et al., Safety-related Regulatory Actions for Biologicals Approved in the United States and the European Union, 300 JAMA 1887, 1887-96 (2008).Google ScholarPubMed

58 Michele Kessler et al., Immunogenicity of Biopharmaceuticals, 21 Nephrol. Dialysis Transplant (Supp. 5) v9, v10-v11 (2006).

59 David M. Dudzinski & Aaron S. Kesselheim, Scientific and Legal Viability of Followon Protein Drugs, 358 JAMA 843, 845 (2008) (citing testimony of Dr. William Hancock, at a hearing before the Senate Committee on the Judiciary, June 23, 2004, available at http://judiciary.senate.gov/hearings/testimony.cfm?id=1239&wit_id=3625 (last visited Nov. 17, 2008)).

60 Patten, P.A. & Schellekens, H., The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development, 112 Dev. Biol. 81–97 (2003).Google ScholarPubMed

61 Covie, A. & Kuhlmann, M.K., Biosimiliars: Recent Developments, 39 Int. Urol. Nephrol. 261, 262 (2007).Google Scholar

62 Louët, Sabine, Lessons from Eprex for Biogeneric Firms, 21 Nature Biotechnology 956, 956-57 (2003).CrossRefGoogle ScholarPubMed

63 Neumann, T.A. & Foote, M., Megakaryocyte Growth and Development Factor (MGDF): An Mpl Ligand and Cytokine That Regulates Thrombopoiesi, 6 Cytokines, Cellular & Molecular Therapy 47, 47–56 (2000).CrossRefGoogle Scholar

64 Lowe, Robert S. et al., Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast, 176 J. Infectious Diseases 1141, 1144-45 (1997);CrossRefGoogle ScholarPubMed Jansen, Kathrin U. et al., Vaccination with Yeast-expressed Cottontail Rabbit Papillomavirus (CRPV) Virus-like Particles Protects Rabbits from CRPV-induced Papilloma Formation, 13 Vaccine 1509, 1509-13 (1995).CrossRefGoogle ScholarPubMed

65 Suzich, supra note 55, at 115555.

66 Dias, Dennis et al., Optimization and Validation of a Multiplexed Luminex Assay to Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18, 12 Clin. Diagn. Lab. Immunol. 959, 959-69 (2005)CrossRefGoogle ScholarPubMed; Luisa L. Villa et al., Immunologic Responses Following Administration of a Vaccine Targeting Human Papillomavirus Types 6, 11, 16, and 18, 24 Vaccine 5571, 5580-83 (2006).

67 Ian Frazer, Correlating Immunity with Protection for HPV Infection, Int. J Infect. Dis. S10, S12 (2007).

68 Margaret Stanley et al., Prophylactic HPV Vaccines: Underlying Mechanisms, 24 Vaccine (Supp. 3) S3/106, S3/108 (2006).

69 US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products, FDA Licenses Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil) for the Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus (2007), http://www.fda.gov/cder/offices/oodp/whatsnew/gardasil.htm (last visited Apr. 14, 2009).

70 Universities Allied for Essential Medicines, Model Provisions for an “Equitable Access and Neglected Disease License” Version 1.0, http://www.essentialmedicine.org/EAL.pdf (last visited April 2, 2009).

71 Samantha Chaifetz et al., Closing the Access Gap for Health Innovations: An Open Licensing Proposal for Universities, 3 Globalization & Health 4 (2007), available at http://www.globalizationandhealth.com/content/3/1/2.

72 See Kapczynski et al, supra note 48, at 1090-91 (describing the self-monitoring system in the EAL proposal).

73 Knowledge Ecology International, The Essential Medical Inventions Licensing Agency, http://www.keionline.org/misc-docs/emila.pdf (last visited Apr. 2, 2009) (hereafter “EMILA”).

74 Effort & Stevens, supra note 29, at 90.

75 See Kapczynski et al, supra note 48; EMILA, supra note 73.

76 Id.

77 U.S. Food and Drug Administration – Office of Generic Drugs Generic Competition and Drug Prices (2006), http://www.fda.gov/cder/ogd/generic_competition.htm (last visited April 3, 2009); Cf. Medecins Sans Frontieres, Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries, at 9, 13-39 (10th ed. 2007), http://www.msf.org/source/access/2007/Untangling_the_Web_10th_ed_2007.pdf (last visited Apr. 4, 2009) (graphing the drop in price for specific drugs after generic drug competition).

78 Gunjan Pradhan Sinha, Shantha Developing $15 Cervical Cancer Vaccine, The Econ. Times, Oct. 16, 2007, http://economictimes.indiatimes.com/News/News_By_Industry/Shantha_developing_15_cervical_cancer_vaccine/articleshow/2461640.cms (last visited Apr. 4, 2009).

79 Frew, Sarah E. et al., The Role of the Domestic Private Sector in Developing Countries for Addressing Local Health Needs, 8 Int. J. Biotechnology 91, 100 (2006).CrossRefGoogle Scholar

80 Milstien, Julie B. et al., Access to Vaccine Technologies in Developing Countries: Brazil and India, 25 Vaccine 7610, 7615 (2007)CrossRefGoogle ScholarPubMed (citing Boston Consulting Group, Global Vaccine Supply: The Changing Role of Suppliers, a Report Commissioned for GAVI by WHO and the World Bank (2005)).

81 Id. at 7615, 7618.

82 Id. at 7614.

83 Frew et al., supra note 80, at 100.

84 See generally Carl Shapiro, Navigating the Patent Thicket: Cross Licenses, Patent Pools and Standard Setting, 1 Innovation Pol’y & the Econ. 119 (2001) (discussing patent pools generally).

85 See generally Knowledge Ecology International, Patent Pools, http://www.keionline.org/index.php?option=com_content&task=view&id=63&Itemid=1 (last visited April 4, 2009); Doctors Without Borders / Medicins Sans Frontiers Campaign for Access to Essential Medicines, http://www.msfaccess.org/ (last visited April 4, 2009); Essential Inventions, Essential Patent Pool for AIDS, http://www.essentialinventions.org/docs/eppa/ (last visited Apr. 4, 2009).

86 Press Release, UNITAID, UNITAID Moves Toward a Patent Pool for Medicines (July 9, 2008), available at http://www.unitaid.eu/en/NEWS/UNITAID-moves-towards-apatent-pool-for-medicines.html.

87 Medical Innovation Prize Fund Act of 2007, S. 2210, 110th Cong. (2007). See also Knowledge Ecology International, Prizes to Stimulate Innovation, http://www.keionline.org/index.php?option=com_content&task=view&id=4&Itemid=1 (compiling reports on the use of prize funds and patent pools to spur biomedical innovation while lowering medicine costs through generic production).

88 Knowledge Ecology International, Working Document – Barbados and Bolivia, Proposal 3, Priority Medicines and Vaccines Prize Fund (PMV/pf), at 2 (2008),http://www.keionline.org/misc-docs/b_b_igwg/prop3_pmv_pf.pdf.

89 Press Release, UNITAID, supra note 87.

90 Chaifetz et al., supra note 71, at 2 (citing Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2005 – From Laboratory to Patient: Pathways to Biopharmaceutical Innovation (2005)).

91 Gregory K. Sobolski et al., Technology Licensing: Lessons from the US Experience, 294 JAMA 3137, 3138 (2005).

92 James Love, UNITAID Patent Pool at Mexico City AIDS Conference, KEI Policy Blog, August 6, 2008, http://www.keionline.org/index.php?option=com_jdwp&Itemid=39&p=135 (last visited Apr. 4, 2009).

93 See Kapczynski et al., supra note 48 (discussing the difficulties of expanding access requirements beyond patents).

94 Agosti & Goldie, supra note 28, at 1908-10.

95 World Health Org. [WHO], Sixty-First World Health Assem. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, WHA61.21, (May 24, 2008).

96 X PRIZE Foundation Press Release, X PRIZE Foundation to Help Fight Tuberculosis Worldwide with Gates Foundation Support, Oct. 16, 2008, http://www.xprize.org/foundation/press-release/x-prize-foundation-to-help-fighttuberculosis-worldwide-with-gates-foundati.